Editorial: sorafenib toxicity, a biomarker of effect?

Clare, Kathleen; Miller, Michael H.; Dillon, John

doi:10.1111/apt.14033

Cited by 4 publications

(1 citation statement)

References 9 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early dermatologic adverse events currently appear to have a more convincing predictor role, since in a prospective study their appearance was significantly correlated with longer OS and time to progression (TTP) compared with patients not experiencing these symptoms, and resulted also correlated with complete response [ 39 , 40 ]. These studies call for research to validate this prognostic correlation, but they also pose further questions on the optimal management of patients without these specific side effects to improve the cost–effectiveness of sorafenib [ 42 ].…”

Section: Sorafenib and Next-to-be-approved Treatmentsmentioning

confidence: 99%

Systemic treatments for hepatocellular carcinoma: challenges and future perspectives

et al. 2018

View full text Add to dashboard Cite

Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, the REFLECT trial showed that lenvatinib is noninferior to sorafenib as front-line treatment. Following these trials, the therapeutic scenario will be dominated by anti-VEGFR drugs, with three different molecules showing a proven anticancer activity. Some open problems still remain and different immunotherapy trials are underway, following promising preliminary results. In this review we analyze: the most recent advancements about patients treated with sorafenib; the results of RESORCE and REFLECT trials; and the ongoing Phase III clinical trials. Finally, we discuss how they could address the current problems and possibly reshape the future of the systemic treatments for HCC.

show abstract

Section: Sorafenib and Next-to-be-approved Treatmentsmentioning

confidence: 99%